Patents matching “antibody”

US 10774141

Antibody for binding to interleukin 4 receptor

SuZhou Connect Biopharmaceuticals, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

US 10772972

Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Sep 15, 2020 · Expires Sep 10, 2040

US 10745471

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. · Granted Aug 18, 2020 · Expires Aug 13, 2040

US 10738112

Anti-human interleukin-17A monoclonal antibody

SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Aug 11, 2020 · Expires Aug 6, 2040

US 10729768

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

TG Therapeutics, Inc. · Granted Aug 4, 2020 · Expires Jul 30, 2040

US 10722594

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

ADC THERAPEUTICS SA · Granted Jul 28, 2020 · Expires Jul 23, 2040

US 10723787

Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 28, 2020 · Expires Jul 23, 2040

US 10683354

Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cells

REGENERON PHARMACEUTICALS, INC. · Granted Jun 16, 2020 · Expires Jun 11, 2040

US 10675358

Antibody adjuvant conjugates

Bolt Biotherapeutics, Inc. · Granted Jun 9, 2020 · Expires Jun 4, 2040

US 10676537

Antibody targeted to tissue factor, preparation method therefor, and use thereof

SHANGHAI MIRACOGEN INC. · Granted Jun 9, 2020 · Expires Jun 4, 2040

US 10676530

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptor

REGENERON PHARMACEUTICALS, INC. · Granted Jun 9, 2020 · Expires Jun 4, 2040

US 10662244

Methods for tumor treatment using CD3XCD20 bispecific antibody

REGENERON PHARMACEUTICALS, INC. · Granted May 26, 2020 · Expires May 21, 2040

US 10633451

Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine

Ludwig-Maximilians-Universitat Munchen · Granted Apr 28, 2020 · Expires Apr 23, 2040

US 10626173

Method for treating pathological angiogenesis by administering an antibody that inhibits APLNR

REGENERON PHARMACEUTICALS, INC. · Granted Apr 21, 2020 · Expires Apr 16, 2040

US 10618967

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Apr 14, 2020 · Expires Apr 9, 2040

US 10620204

Antibody-mediated neutralization of Ebola viruses

The Board of Regents of the University of Texas System · Granted Apr 14, 2020 · Expires Apr 9, 2040

US 10596270

Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates

Sutro Biopharma, Inc. · Granted Mar 24, 2020 · Expires Mar 19, 2040

US 10570185

Method to detect autoantibody reactivity for deamidated insulin autoantigen in diabetes

Northwestern University · Granted Feb 25, 2020 · Expires Feb 20, 2040

US 10562975

CD6 antibody for treatment of T-cell mediated diseases or disorders

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Feb 18, 2020 · Expires Feb 13, 2040

US 2020040086

PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY

BERLIN CHEMIE AG [DE] · Granted Feb 6, 2020 · Expires Feb 1, 2040

US 10550193

Methods and antibody compositions for tumor treatment

REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2020 · Expires Jan 30, 2040

US 10548987

Antibody-drug conjugates for targeting CD56-positive tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 4, 2020 · Expires Jan 30, 2040

US 10544223

Combination therapy with an anti-axl antibody-drug conjugate

ADC THERAPEUTICS SA · Granted Jan 28, 2020 · Expires Jan 23, 2040

US 10544232

Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody

REGENERON PHARMACEUTICALS, INC. · Granted Jan 28, 2020 · Expires Jan 23, 2040